ELECTRICAL IMPEDANCE MYOGRAPHY IN ALS

ALS 中的电阻抗肌电图检查

• 批准号: 8167023
• 负责人: JAMES B CARESS
• 金额: $ 1.21万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2011-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167023
• 关键词: Amyotrophic Lateral Sclerosis; Breathing; Computer Retrieval of Information on Scientific Projects Database; Data; Deterioration; Disease Progression; Enrollment; Funding; Goals; Grant; Institution; Measures; Methods; Muscle; Myography; Nerve; Outcome Measure; Painless; Patients; Research; Research Personnel; Resources; Source; Surveys; Testing; United States National Institutes of Health; electric impedance; functional status

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Trials evaluating new therapies for stopping or slowing the progression of amyotrophic lateral sclerosis (ALS) depend critically upon the use of outcome measures to assess whether a potential treatment is effective. The more effective an outcome measure, the fewer patients need to be enrolled and the shorter the trial. Many outcome measures have been used over the years, including strength assessments, breathing tests, functional status surveys, and nerve testing, but all are far from ideal. A new method, called electrical impedance myography (EIM) appears to be especially promising in that it provides very consistent data from one testing session to the next, is sensitive to the muscle deterioration that occurs in ALS, and is entirely painless and non-invasive. In this study, investigators from multiple institutions plan to compare several different outcome measures, including EIM, in approximately 120 ALS patients, with each patient being followed for a period of one year. All of these measures will be compared to one another and an assessment of their ability to detect disease progression made. Our goal will be to determine whether EIM can serve as a valuable new outcome measure, ultimately leading to substantially faster, more effective ALS trials requiring fewer patients.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 评估新疗法的试验，以停止或减慢肌萎缩性侧面硬化症（ALS）的进展，这取决于使用结果指标来评估潜在治疗是否有效。结局措施越有效，需要招募的患者就越少，并且试验越短。多年来，已经使用了许多结局指标，包括力量评估，呼吸测试，功能状态调查和神经测试，但远非理想。一种称为电阻抗密闭（EIM）的新方法似乎特别有前途，因为它提供了一个非常一致的数据，从一个测试会话到下一个测试，对ALS中发生的肌肉恶化敏感，并且完全无痛且无侵入性。在这项研究中，来自多个机构的研究人员计划比较大约120名ALS患者在内的几种不同的结果指标，包括EIM，每位患者持续一年。所有这些措施将相互比较，并评估其检测疾病进展的能力。我们的目标是确定EIM是否可以作为有价值的新结果指标，最终导致更快，更有效的ALS试验需要更少的患者。